Pharmaceutical R&D subsidiary
Appears in 1 story
Sold BBT001 and BBT002 assets to Bambusa; collaboration partner
Bambusa Therapeutics, a Boston biotech founded in March 2024, filed Friday to sell stock to the public. The proceeds are earmarked for larger trials of its lead eczema drug and a respiratory candidate, part of the $150 billion immunology and inflammation market the company targets with bispecific antibodies.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
